Jim Cramer is seeing signals that money managers are preparing for a Democratic landslide. He outlines what it could mean for stocks.
Jefferies downgrades Pfizer to hold from buy.
Researchers are working on opioids with all the painkilling power of current drugs but with less risk of addiction or overdose.
Jim Cramer says uncertainty surrounding a Democratic win for the White House puts drug stocks in the danger zone.
The Philippine President's off-the-cuff comments seem like rhetoric but he's made good on promises to target crime and corruption, says Oxford Economics' Oliver Salmon.
Shares of Bristol-Myers Squibb fell 10 percent, after the Opdivo trial result did not meet expectations.
CNBC's Meg Tirrell reports on why billions are at stake for Bristol-Myers and Merck. The “Fast Money” traders weigh in.
CNBC's Julia Boorstin reports the latest on Facebook's Marketplace as within hour of launch, illegal sales were taking place on the platform.
Duterte says he would 'be happy' to exterminate three million drug users and peddlers in the country.
Over 3,100 people have been killed since Duterte came to power on a pledge to end drugs and corruption in the country.
A house exploded Tuesday morning in the Bronx killing a FDNY battalion chief and injuring at least 12 people, according to a NBC New York report.
Former FDA Deputy Commissioner Scott Gottlieb, M.D. weighs in on Mylan's pricing outrage and what's really driving drug price hikes.
Philippine President Rodrigo Duterte invited UN Secretary-General Ban Ki-moon and the European Union to investigate his anti-drugs crackdown.
Sarepta soars on FDA approval. Stephen Weiss, Short Hills Captial, discusses how investors should approach the name.
Wells Fargo's $185 million settlement, and Mylan's EpiPen mess were about corporate greed, the Aspen Institute CEO says.
A serious warning on Pfizer's quit smoking drug should be removed, panelists to the U.S. Food and Drug Administration recommended on Wednesday.
David Maris, Wells Fargo Securities, and CNBC's Meg Tirrell talk about rebates, the outrage over drug prices and Hillary Clinton's drug price plan.
CNBC's Meg Tirrell reports on how Hillary Clinton's policies on drug pricing will impact the industry and investors.
CNBC's John Harwood reports on Hillary Clinton's new plan aimed to tackle drug price hikes.
Mylan's EpiPen price hike is just the latest in a series of "poor management" decisions by the board, NYC Comptroller Scott Stringer tells CNBC.